Benzinga | Sep 14, 2021 07:31AM EDT

Accuray Says Data From PACE Trial Indicate CyberKnife Is 'Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients'

Accuray Incorporated (NASDAQ:ARAY) announced today that data from the PACE -- Prostate Advances in Comparative Evidence -- trial indicate the company's CyberKnife(r) robotic radiotherapy platform is superior to conventional linear accelerators in reducing the incidence of late grade two or higher bladder toxicity associated with prostate cancer stereotactic body radiation therapy (SBRT) treatments. The two-year follow-up data presented at the European Society for Radiotherapy and Oncology annual congress showed that bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT.